Biopharma Takes on Deadly Brain Cancer After Decades of Failure

After decades of failed clinical trials for glioblastoma, cell and gene therapies are starting to provide hope. Carl June, MD, the Richard W. Vague Professor in Immunotherapy, has predicted that CAR T cell therapy will make a difference for the deadly brain cancer. Early results reported this year from a Phase I clinical trial at Penn Medicine’s Abramson Cancer Center showed that a “dual-target” approach shrank brain tumors in a handful of patients.